A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with overlap myelodysplastic/myeloproliferative neoplasms (MDS/MPN) or primary myelofibrosis (PMF)
暂无分享,去创建一个
A. Jankowska | J. Maciejewski | Y. Saunthararajah | A. Raza | A. Advani | M. Sekeres | M. Kalaycio | J. Chan | R. Tiu | N. Bejanyan | Lindsey Mooney